June 10 (Reuters) - Data from Eli Lilly's ( LLY ) late

stage trial on experimental obesity pill orforglipron is

expected in April 2025, a top Eli Lilly ( LLY ) executive said

on Monday.

The pill is part of a class of drugs known as incretins

designed to mimic the action of the GLP-1 hormone, which helps

regulate blood sugar, slow the rate at which the stomach empties

of food and decrease appetite.